Is a randomized trial necessary to determine whether endovascular repair is the preferred management strategy in patients with ruptured abdominal aortic aneurysms?  by Veith, Frank J. et al.
TRANS-ATLANTIC DEBATE
Thomas L. Forbes, MD, and Jean-Baptiste Ricco, MD, PhD, Section Editors
Is a randomized trial necessary to determine whether
endovascular repair is the preferred management
strategy in patients with ruptured abdominal aortic
aneurysms?
Frank J. Veith, MD,a Janet T. Powell, PhD, MD, FRCPath, andb Robert J. Hinchliffe, MD, FRCS,c New
York, NY, and Cleveland, Ohio; and London, United Kingdom
Mortality rates following repair of ruptured abdominal aortic aneurysms have remained depressingly high over the last
number of decades despite advances in anesthesia and perioperative care. Prior to the introduction of endovascular repair,
refinements in surgical technique had been few and far between. It was not until fairly recently that we finally observed
a reduction in mortality coinciding with the wider adoption of endovascular repair. So, the case is closed, right?
Endovascular repair should be widely adopted in all suitable patients? Well, not exactly. The following debate centers
around what level of evidence is required to answer this question.
Frank Veith argues that we’re already there. He was an early adopter and innovator of endovascular techniques and
feels that we have enough information to widely adopt endovascular repair of ruptured aneurysms. Janet Powell and
Robert Hinchliffe, innovators in their own right, feel that the generalizability and applicability of endovascular repair
require further evaluation with a randomized trial. Both offer clear and reasoned arguments. ( J Vasc Surg 2010;52:
1087-93.)PART I: IT IS NOT NECESSARY TO PERFORM
A RANDOMIZED TRIAL TO COMPARE OPEN
AND ENDOVASCULAR REPAIR OF RUPTURED
ABDOMINAL AORTIC ANEURYSMS
—FrankJ.Veith,MD,NewYork,NY,andCleveland,Ohio
This article addresses the question whether or not a
randomized controlled trial (RCT) comparing endovascu-
lar repair (EVAR) with open repair for ruptured abdominal
aortic aneurysms (RAAAs) is needed. Many single-center
reports, meta-analyses, and population-based studies have
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doi:10.1016/j.jvs.2010.05.142shown a substantially lower 30-day mortality for EVAR
than open repair in the RAAA setting. However, it is
possible that this difference is due to patient selection, with
open repair being sometimes used in higher-risk patients
than EVAR. In addition, some comparative trials have
failed to find better mortality outcomes after EVAR than
after open repair. For this reason, RCTs have been pro-
posed. A recently completed review of the collected world
experience with EVAR for RAAAs included data from 13
centers in which EVAR was used to treat almost all RAAAs
in patients with suitable anatomy irrespective of hemody-
namic status or risk status. In these centers, the 30-day
mortality for EVAR treatment was 19.7%, whereas 30-day
mortality for open repair was 36.3% (P  .0001). Several
treatment strategies, adjuncts, and technical factors were
felt to be important in achieving this lower mortality for
EVAR. These included use of a standardized RAAA proto-
col and adequate EVAR experience, fluid restriction and
hypotensive hemostasis, appropriate techniques for achiev-
ing supraceliac aortic balloon control and use of such
control only when necessary, early detection and appropri-
ate treatment of abdominal compartment syndrome, and
use of EVAR in the treatment of the worst-risk patients.
Because of these results in the 13 centers, none of which
would participate in a RCT of EVAR vs open repair for
RAAAs and because of logistical and ethical considerations,
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preferential use of EVAR to treat RAAAs in patients with
suitable anatomy for the procedure.
Endovascular repair of a ruptured abdominal aortic
aneurysm (RAAA) was first performed successfully by
Marin et al on April 21, 1994.1 Another case was first
reported by Yusuf et al in 1994.2 Since then, many centers
have used endovascular aneurysm repair (EVAR) to treat
RAAAs, with varying results.3-13 Several groups have devel-
oped standardized systems of management in the RAAA
setting, have used EVAR whenever possible, and have
achieved good results with EVAR.3-10 In contrast, other
authors have used EVAR for RAAAs more selectively and
have reported no better results with EVAR than with
traditional open repair.11-13
On the basis of these many reports, it is fair to say that
the comparative efficacy of EVAR and open repair for
RAAAs is controversial and that randomized, prospective
comparative trials of the two treatmentmethods are needed
with this entity. This article will show why this is not the
case and why there is sufficient evidence without such trials
to show that all RAAAs with anatomy suitable for EVAR
should be treated in this way.
THEORETIC CONSIDERATIONS
EVAR has been used increasingly to treat patients with
RAAAs and offers many theoretic advantages over open
repair. It is less invasive, eliminates damage to periaortic
and abdominal structures, decreases bleeding from surgical
dissection, minimizes hypothermia, and lessens the require-
ment for deep anesthesia. Because of these potential advan-
tages and reports of lower procedural mortality, EVAR has
been deemed superior to open repair for the treatment of
RAAAs.3-10
Collected world experience with EVAR for RAAAs.
Between July 1, 2002, and January 15, 2009, data were
collected from 49 centers around the world performing
EVAR for RAAAs. Some of these data were from 13 centers
that were committed to EVAR and performed this proce-
dure on all or almost all RAAAs in patients who had suitable
aortic neck and iliac artery anatomy for EVAR. The data
from these 13 centers was updated to January 15, 2009.5
The overall collected data with the use of EVAR to treat
1037 patients with a RAAA or a ruptured aortoiliac aneu-
rysm show an overall 30-day mortality of 21.2%. This
30-day mortality is clearly less than the rate of 35% to 55%
after open repair for RAAAs, as reported in multiple stud-
ies.14 In the collected experience, however, many of the
centers limited the use of EVAR to “stable” RAAA patients
or even those with “contained” ruptures. Because hemo-
dynamic instability is associated with a higher risk of pro-
cedural mortality,6,8,14 it is invalid to compare the lower
procedural EVAR mortality rates with those for open re-
pair.
Because of this, the updated outcomes for EVAR were
examined in the selected group of 13 centers that were
committed to performing EVAR to treat all RAAA patients
who were anatomically suitable for endograft treatment,including those that were hemodynamically unstable and
those in profound shock.5 These centers were usually the
ones with the larger experience. Although there was some
variability in the approach of these centers to the treatment
of RAAA patients, most had some degree of standardiza-
tion andmany had a defined protocol. All were experienced
in the use of EVAR and endovascular adjuncts for elective
abdominal aneurysm treatment and all had dedicated en-
dovascular facilities and imaging equipment.
Despite the use of EVAR to treat almost all anatomi-
cally suitable RAAA patients, the 30-day mortality for
EVAR in 680 patients was a favorable 19.7% (range, 0%-
32%).5 These same 13 centers performed open repair for
RAAAs in 763 patients who had anatomy unsuitable for
EVAR during this same period, and the 30-day mortality
for open repair was 36.3% (range, 8%-49%; P  .0001 for
EVAR vs open repair).5
These updated comparative outcome results (30-day
mortality 19.7% for EVAR vs 36.3% for open repair) from
these 13 centers committed to EVAR treatment of all
possible RAAAs strongly suggest that EVAR is a superior
way to treat RAAAs in those patients who have aortic neck
and iliac anatomy suitable for endovascular graft treatment.
Additional proof that EVAR is a better treatment for some
RAAA patients is that 10% to 15% of patients in this
collected experience, who were categorically unsuitable or
prohibitively high risk for open repair, survived for many
years after EVAR.5
REASONS FOR VARIABLE RESULTS WITH
EVAR FOR RAAAS
There are several possible reasons that might explain
the discordant results for RAAA treatment by EVAR re-
ported by different authors.3-13 Among these reasons is the
importance of several strategies, adjuncts, and technical
factors that are thought to influence the outcome of
EVAR treatment for RAAAs and which probably account
for the favorable EVAR outcomes in the 13 centers in the
collected experience committed to perform EVAR
whenever possible5:
1. Standard approach or protocol. These allow the
most effective decision making and treatment of these
patients in what are often confusing and stressful circum-
stances.9,10 They are also important to facilitate education
in and recognition of RAAAs by generalists, emergency
department personnel, and others to enable early diagnosis
and mobilization of the specialized care givers best trained
to optimize treatment.
2. Fluid restriction (hypotensive hemostasis). Fluid
resuscitation should be restricted, even if the patient be-
comes hypotensive. Experience has shown that systolic
arterial pressures of 50 to 70 mm Hg are well tolerated for
short periods and limit internal bleeding and its associated
loss of platelets and clotting factors.4-6,10,15 Whether phar-
macologic lowering of blood pressure is beneficial remains
to be conclusively shown.6,10
3. Treatment site. EVAR procedures are optimally
performed in a site equipped for excellent fluoroscopic
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require open repair or open adjuncts to their EVAR.
4. Anesthesia and catheter-guidewire placement.
The latter should be obtained percutaneously under local
anesthesia. This permits arteriography to define aortic and
arterial anatomy, facilitates large sheath and supraceliac
balloon placement if needed, and prevents circulatory col-
lapse caused by the induction of general anesthesia.
Whether general anesthesia is used later to eliminate mo-
tion and improve fluoroscopic imaging to permit precise
graft deployment remains controversial. One group has
successfully used local anesthesia supplemented by sedation
throughout as an alternative.3,6,10
5. Supraceliac aortic sheath placement and balloon
control. Most groups favor their use only when there is
severe circulatory collapse. In such cases, deflation of the
balloon before sealing of the rupture site will result in
immediate recurrence of the circulatory collapse. There-
fore, techniques have been developed to maintain contin-
uous aortic control until the endograft has sealed the
leak.4-6,10,16,17 These techniques use multiple balloons to
minimize renal and visceral ischemia by placing secondary
balloons within the endograft as the supraceliac balloon is
deflated and removed through its supporting sheath.
6. Endograft type and configuration. Bifurcated
and aortouniiliac (or femoral) grafts can both be used
successfully, although some patients have unilateral iliac
disease that mandates a unilateral configuration. Modular
and unibody grafts have been used successfully in both
configurations. An appropriate inventory of suitable grafts
and accessories must be stocked sterile in the treatment site
and be available for the procedure and unexpected contin-
gencies.
7. Abdominal compartment syndrome. Abdominal
compartment syndrome is a major cause of morbidity and
mortality after EVAR for RAAA. It is advantageous to keep
a high index of suspicion for this entity. Laparotomy and
hematoma evacuation have alleviated the hypotension,
high ventilatory compliance, and oliguria that occurs with
the full-blown syndrome. Monitoring bladder pressure has
been helpful in the early detection of the syndrome,6,10 and
early laparotomy with open abdomen treatment and suc-
tion/sponge (vacuum-assisted closure) dressings may de-
crease mortality and allow survival in otherwise hopeless
circumstances when small bowel and mesenteric edema
cause loss of domain for the abdominal viscera.10,18
8. EVAR for worst-risk patients. It is probable that
EVAR is most beneficial in augmenting survival when it is
used in the worst-risk patients who are unlikely to survive
open repair. Patients with hemodynamic instability and
profound circulatory collapse, a hostile abdomen, or those
unable to receive a transfusion would fall in this category. If
such patients, particularly those who are hemodynamically
unstable, are excluded from EVAR, it is likely that the
improved survival that can accrue from this form of treat-
ment will be diminished.5
The reduced 30-day mortality after EVAR (19.7%)
compared with patients treated by open repair (36.3%),together with the ability to obtain survival in many RAAA
patients who were prohibitive risks for open repair, consti-
tute strong evidence that EVAR is a better way to treat
RAAAs, at least in some patients, provided the described
strategies, adjuncts, and techniques are used.
Thus, in response to the question “Is there a need for a
randomized controlled comparison of EVAR and open
repair in RAAA patients?,” it is clear the answer is no. The
data from the collected experience inmany centers5 suggest
that an RCT is not needed. If those who believe such
evidence is necessary to confirm the value of EVAR in the
RAAA setting wish to perform such trials, these results are
awaited with interest. However, such studies will be diffi-
cult to perform, and many believe such studies will be
unnecessary and unethical in view of the experience that has
thus far been obtained in this morbid and life-threatening
condition.
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PART II: A RANDOMIZED CONTROLLED
TRIAL IS THE BEST WAY TO DETERMINE
WHETHER ENDOVASCULAR REPAIR IS THE
PREFERRED MANAGEMENT STRATEGY IN
PATIENTS WITH A RUPTURED AORTIC
ANEURYSM
Janet T. Powell, MD, and Robert J. Hinchliffe,
MD, London, United Kingdom
Open repair is the standard management of ruptured
abdominal aortic aneurysms worldwide. Endovascular re-
pair is an attractive alternative that shows promise in pre-
liminary studies but is available to few patients. In most
countries, a major reconfiguration of vascular services
would be required to make endovascular repair available to
all patients presenting to the hospital with ruptured aneu-
rysm. The evidence to underpin such a major change in the
delivery of care is lacking, with current observational stud-
ies subject to serious confounders. Like all other surgical
innovations, endovascular repair of ruptured aneurysms
should be assessed in large, pragmatic, randomized con-
trolled trials. Only these will provide the necessary evidence
to persuade health care policy makers to reorganize the
delivery of care to patients with ruptured aneurysm.
Should the potential benefits and risks of endovascular
repair (EVAR) of ruptured abdominal aortic aneurysm
(RAAA) on a population-based or national scale be evalu-
ated by evidence or by expert opinion? By evidence, of
course, with the best evidence coming from randomized
controlled trials (RCTs).
The evaluation and assessment of the role of EVAR for
RAAA depends on numerous factors, including the pa-
tient’s physiologic condition and anatomy, the decision to
intervene, the skills of the operators and their teams, learn-
ing curves, the availability of EVAR in different centers, and
the perception of equipoise. A few well-equipped and well-
organized pioneering centers report excellent results with
EVAR. Similarly, a few pioneering centers report excellent
results for elective laparoscopic repair of aneurysms. How-
ever, in neither case is there yet good-quality evidence to
support the widespread adoption of these practices.
The recent Innovation-Development-Exploration-
Assessment-Long-term (IDEAL) follow-up recommenda-
tions have set out the essential stages in the introduction of
innovative surgical techniques into widespread practice:
“No surgical innovation without evaluation.”1 These arethe recommendations (see Table I) that health care policy
makers and commissioners will use as a guide to evaluate
the utility of EVAR for RAAA.
The “innovation” was reported in 1994,2 and since
then “development” of EVAR for RAAA has occurred in a
few centers (Zurich, New York, and Malmö; Table I).3-5
The “development” has resulted in specific protocols,
which include use of aortic occlusion balloons to permit
rapid hemorrhage control and the open abdomen tech-
nique to avoid the damaging effects of compartment syn-
drome.
New technologies and procedures in patients must be
reported, whether successful or not.1,6 However, the ten-
dency with EVAR for RAAA has been only to report
successful procedures, with most case series reporting fa-
vorable results.7 Publication bias results in unfavorable
results not being reported. In addition, the selection of
patients is poorly reported in cohort studies, and some
studies do not discriminate between urgent and ruptured
aneurysms. Case selection may underlie the impressive re-
sults achieved in specialist centers using both EVAR and
open repair: some centers report a very low mortality from
open repair of RAAA, but in general, the results remain
disappointing, with around 40% to 50% perioperative mor-
tality.8,9 The sequential reporting of all cases (endovascular
and open) may unmask some of the case selection bias, and
a standardized format for reporting would facilitate assess-
ment of major comorbidities and confounders,6 Unfortu-
nately, no standardized reporting format for the outcome
of RAAA has been developed.
The “exploratory” phase of IDEAL is based on the
reporting of the first few hundred cases in prospective
research databases as well as from exploratory randomized
Table 1. The IDEAL1 recommendations and
endovascular repair of ruptured abdominal
aortic aneurysm
IDEAL stage Description Citation
Innovation First case described Yusuf,2 1994
Development Protocols developed and
associated problems
addressed in a handful
of centers
Mayer,3 2009
Mayer,4 2009
Malina,5 2005
Exploration Pilot RCT Hinchliffe,10 2006
Exploratory analysis of
national database
Egorova,11 2008
Holt,12 2010
Assessmenta AJAX, ECAR,
IMPROVE RCTs in
progress
Trialists,14 2006
Desgranges,15 2010
Powell,16 2009
Long-term
follow-upa
Currently limited to case
series
Hinchliffe,13 2007
AJAX, Amsterdam Acute Aneurysm Trial; ECAR, Ruptured Aorta-Iliac
Aneurysms: Endo vs Surgery; IDEAL, Innovation, Development, Explora-
tion, Assessment, and Long-term follow-up; IMPROVE, Immediate Man-
agement of the Patient with Ruptured Aneurysm: Open Versus Endovascu-
lar repair; RCT, randomized controlled trial.
aStages not completed.trials, and the data from such studies provide the informa-
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domized trial demonstrated the feasibility of randomizing
patients in the emergency situation and highlighted many
of the organizational difficulties.10 Intriguingly, 30-day
mortality was not different in those undergoing open sur-
gery or EVAR.10
The results of publically funded randomized trials are
always reported, whether favorable or not. The Medicare
data set in the USA and the Hospital Episode Statistics
(HES) data in the UK have been inspected for outcomes
and showed better outcomes for endovascular repair
than open repair, with 30-day mortalities of about 21%
to 30%.11,12 Such studies suffer from strong patient
selection bias, confounders cannot be eliminated, and
the patient cohorts likely include both urgent (symptom-
atic) and ruptured aneurysms. Currently, there is a pau-
city of data on the long-term outcomes of patients
having undergone emergency EVAR, although the Zu-
rich group presented data on 5-year outcomes at the
European Surgical Association in Budapest in May 2010.
There are suspicions regarding the durability of stent
grafts, and the number of secondary interventions may
be significant.13 A life-saving parachute (open repair) has
existed for patients with RAAA for 50 years. The
question now is which design of parachute (open repair
or stent) is a better buy? “Assessment” is essential, and
RCTs will confirm which parachute is the best buy.
The RCT is the gold standard for the “assessment” of
surgical innovations. There are two main types of RCTs.
Exploratory trials seek to assess whether an intervention or
surgical procedure can work, such as the Amsterdam Acute
Aneurysm Trial (AJAX) and Ruptured Aorta-Iliac Aneu-
rysms: Endo vs Surgery (ECAR) trials for RAAA.14,15 Their
results will add to the “development” evidence from spe-
cialist centers [3-5]. There also are large, pragmatic multi-
center trials with cost-effectiveness evaluations that seek to
inform clinical policy and decision making for populations,
and here, the Immediate Management of the Patient with
Ruptured Aneurysm: Open Versus Endovascular repair
(IMPROVE) trial is the example for RAAA.16 Such trials
should be followed by “long-term monitoring” to report
any delayed adverse events.
The only other evidence currently available about the
potential benefits of EVAR for RAAA comes from system-
atic reviews and meta-analyses of published cohort studies,
which suffer from heterogeneity, under-reporting of poor
results, and inadequate adjustment for confounders.7
These systematic reviews cannot be considered adequate
evidence, as recognized by most of their authors, who
conclude with the demand for a randomized trial.
The morphologic limitations of EVAR, with perhaps
only about 60% of RAAAs having suitable anatomy, the
willingness of clinicians to transfer a patient to the com-
puted tomography scanner when they are actively hem-
orrhaging, uncertainty about the true physiologic effects
of endovascular repair, including compartment syn-
drome, contrast-induced renal failure, the consequences
of endoleak, patient outcomes from nonexpert centers,the paucity of data on patients turned down for any
intervention, and a lack of standardized reporting criteria
are issues that cannot be addressed adequately by single-
center experiences, databases designed for routine ad-
ministrative purposes, or systematic reviews (Table II).
In contrast, large, pragmatic multicenter RCTs can ad-
dress all of these issues.
History is full of examples of where the conclusions
drawn from observational studies have been overturned by
RCTs. Our opponent has had direct experience of this in
the use of polytetrafluoroethylene grafts for critical limb
ischaemia.17,18 The amazing results of absorbable metal
stents on the treatment of critical limb ischemia were
overturned by a RCT.19,20 Other examples taken from
outside vascular surgery, where large pragmatic RCTs have
overturned the findings from observational studies, include
the Corticosteroid Randomisation After Significant Head
Injury (CRASH) trial of corticosteroids in acute head injury
and the randomized trial of estrogen plus progestin for
secondary prevention of cardiovascular events in post-
menopausal women.21,22
Large pragmatic trials, like IMPROVE, take account of
a number of features that may be unique to surgical trials,
including imbalance in surgical and associated expertise,
variation in standards of general health care, and cardiovas-
cular risk prevention, which are particularly relevant in the
area of vascular surgery and ruptured aneurysm, and varia-
tion in the standards of aftercare, including nursing and
rehabilitation. For trials of emergency surgery there are
other issues, including geographic provision of services,
distance the patient travels to an emergency center, anes-
thetic expertise, access to critical care facilities, transfer, and
financial arrangements. None of these issues are addressed
by cohort studies, systematic reviews of cohort studies, or
administrative databases. In contrast, these real-life service
and policy issues can be addressed by large, multicenter
RCTs (Table II). Moreover, only data from the RCTs or
mandatory registries will give us good reporting of the
long-term balance of risks and benefits and whether any
early survival advantage is maintained.
In conclusion, in the “exploratory” phase of EVAR
for RAAA, the only pilot trial has shown no difference in
30-day mortality between endovascular and open re-
pair.10 The AJAX trial14 is being extended because the
results of EVAR were not as good as anticipated from the
literature. Irrespective of the reports of the good out-
comes after EVAR from single expert centers or admin-
istrative databases, all these results are heavily con-
founded by patient selection and risks are under-
reported. We need better evidence to guarantee the best
outcomes for future patients with aneurysm rupture. We
need to know whether an attempt at EVAR would be
beneficial for all patients. It is only such knowledge that
will drive changes in the provision of health care services
to benefit future patients.
The front cover of the September 26, 2009, issue of
The Lancet, which published the IDEAL statements,
carried this sentence: “It is incumbent on academic
, rupt
t, and
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ered a comic opera into a dynamic world-class specialty.”
We need to assess surgical innovations, including endo-
vascular repair for ruptured aneurysm, rapidly in large,
pragmatic RCTs.
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Given the poor outcomes after open repair for ruptured ab-
dominal aortic aneurysms (RAAAs), as well as the low 30-day
mortality associated with endovascular aneurysm repair (EVAR) in
elective patients, an increasing numbers of centers have established
protocols to use EVAR for RAAA.
In this debate, Frank Veith defends the motion that a random-
ized controlled trial (RCT) is not needed because there is sufficient
evidence to show that RAAAs with appropriate anatomy should be
treated endovascularly. In fact, by 2005 up to 17% of RAAAs were
treated endovascularly in the United States.1 However, in many of
these pioneering centers that reported excellent results with EVAR
for RAAA, patients continue to undergo open repair between 53%
and 64% of the time.2 In addition, the proportion of RAAAs
anatomically suitable for EVAR is between 47% and 67%,3 some-
what limiting the applicability of the endovascular technique in this
setting.
Dr Veith’s summary of the world experience goes a long way
to prove that EVAR is the preferred treatment in centers such as
New York, Albany, Seattle, Calgary, and Malmö, and others with
the appropriate experience, protocols, and infrastructure. How-
ever, how generalizable are these results to other centers without
this experience? Can all patients expect the same results as those
lucky enough to have been treated at these centers?
Janet Powell and Robert Hinchliffe have a different view and
consider the need for further evidence to support widespread
adoption and funding of EVAR for RAAA by health care policy
makers. They argue that the only evidence available now about the
benefits of EVAR for RAAA comes from systematic reviews of
cohort studies with poor adjustments for confounders. In fact, the
only pilot RCT shows comparable 30-day mortality in RAAA
patients undergoing EVAR and open repair. They defend a prag-
matic RCT, including unstable patients with the clinical diagnosis
of RAAA at the point of randomization to undergo immediate
computed tomography (CT) scan with EVAR whenever possible,
or open repair, in which case a CT scan is optional.
The difficulties of such a study are evident and include selec-PhD, London, Ontario, Canada; and Poitiers, France
instant accessibility of a CT scanner and an operating room dedi-
cated to EVAR at all times, informed consent in hemodynamically
unstable patients, anesthetic expertise using a structured protocol
with hypotensive hemostasis, endovascular and surgical expertise
available anytime, availability of a large choice of stent grafts, use of
aortic balloon occlusion in hemodynamically unstable patients,
access to critical care facilities, and surveillance for abdominal
compartment syndrome. Although not insurmountable, some of
these factors will complicate the operation and interpretation of
this RCT and likely lengthen its recruitment period.
In summary, both parties agreed that endovascular repair of
RAAA saves lives, but they differ when considering the applicability
of EVAR in these emergency situations. Frank Veithmaintains that
we have enough clinical evidence to use EVAR in the subset of
RAAA patients with favorable anatomy. Janet Powell and Robert
Hinchliffe believe that an RCT is required to obtain more gener-
alizable information. Either way, the introduction of EVAR of
RAAAs has been an exciting and life-saving innovation, and we
await further information regarding its use and applicability, ran-
domized or not.
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